Effect of the combination of ethinyl oestradiol and chlormadinon acetate on sexuality

Abstract

From the variety of modern methods of hormonal contraception available in the arsenal of the obstetrician-gynecologist, preference is given to those that include gestagen, which not only reduces the clinical manifestations of androgenous dermopathy, but also increases sexual function, at least not affecting it negatively. Such combined oral contraceptives include Belara, containing chlormadinone acetate 2mg, and ethinyl oestradiol 0.03mg. The choice of this drug is justified by previous studies, which evaluated its safety and ability to stop androgenous dermopathy. At the same time, the impact on sexual function was not taken into account in these studies. The purpose of the study was to determine the effect of combined oral contraceptive containing chlormadinone acetate 2mg, and ethinyl oestradiol 0.03mg on sexual function.
Material and methods. There were examined 68 patients who were prescribed a combined oral contraceptive containing chlormadinone acetate 2mg, and ethinyl oestradiol 0.03mg (Belara) – one tablet for 21 days daily, followed by a seven-day break. The female sexual function index (FSFI) was investigated in dynamics. Statistical data processing was carried out by STATISTICA 13.3 (Tibco, USA).
Results. There were registered the positive effects on sexual health, which consisted in improving all indicators of female sexual function index.
Conclusion. The combined oral contraceptive containing chlormadinone acetate 2mg, and ethinyl oestradiol 0.03mg may be recommended to patients with reduced sexual function as a drug of choice, as well as when reducing sexual function on the taking other contraceptives.